AbbVie partners with Iambic to deploy its AI molecular superintelligence platform, while Telix Pharmaceuticals agrees to acquire radioisotope leader ITM.
|Articles|November 20, 2007
Sarah Houlton
Advertisement
Sarah Houlton
International Correspondent
Sarah Houlton is the international correspondent for Pharmaceutical Executive, covering industry and regulatory issues around the world from her base in London. She is a freelance journalist, specializing in the pharmaceutical and chemical industries. Her background is scientific – her PhD in organic synthesis was sponsored by Glaxo, and she also worked for the James Black Foundation as a research chemist. Sarah was the editor-in-chief of Manufacturing Chemist magazine for several years and now writes for a range of industry publications in both Europe and the United States, as well as undertaking technical writing projects on behalf of several laboratory equipment manufacturers. She also writes about her biggest passion - soccer.
Advertisement
Related to this article
Novo Nordisk reports that CagriSema delivered 12.4% average weight loss in a late-stage diabetes trial, outperforming tirzepatide's 9.1% at comparable doses.
Inovalon's Jen Lamppa on how real-time clinical data feeds validate patient eligibility at enrollment — reducing burden while improving accuracy.
FDA approves Ultragenyx's Fayuvi as the first treatment for Sanfilippo syndrome type A, Lisata Therapeutics acquires Marea Therapeutics as mAbxience partners with Sandoz on a hemophilia A biosimilar, and Joe Cunningham argues that executive drug-pricing deals alone won't fix costs.
Lisata Therapeutics acquires Marea Therapeutics and secures $225 million in concurrent financing, while mAbxience and Sandoz partner to develop and globally commercialize an emicizumab biosimilar.
FDA approved Ultragenyx's Fayuvi (rebisufligene etisparvovec-hopf) as the first treatment for MPS IIIA Sanfilippo syndrome type A.
Former Rep. Joe Cunningham (D-SC), now spokesperson for the Pharmaceutical Reform Alliance, argues that codifying Most-Favored-Nation pricing into law is the real fix for drug costs.
Former U.S. Representative Joe Cunningham (D-SC), spokesperson, Pharmaceutical Reform Alliance. dismisses the pharmaceutical industry's innovation argument against MFN pricing.
Advertisement
Advertisement
Trending on PharmExec
1
Understanding the Latest with MFN Pricing and What It Means to Pharma
2
FDA Approves Fayuvi for Pediatric Patients with Sanfilippo Syndrome Type A
3
The Battle to Own the GLP-1 Patient Journey
4
Novo Announces Drug Discovery Collaboration with Anthropic
5